OPK vs. PCRX, TARO, AVIR, HRMY, ADCT, FOLD, CLDX, GERN, MYGN, and NVAX
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Pacira BioSciences (PCRX), Taro Pharmaceutical Industries (TARO), Atea Pharmaceuticals (AVIR), Harmony Biosciences (HRMY), ADC Therapeutics (ADCT), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Geron (GERN), Myriad Genetics (MYGN), and Novavax (NVAX). These companies are all part of the "medical" sector.
OPKO Health (NASDAQ:OPK) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.
OPKO Health has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
OPKO Health currently has a consensus price target of $3.17, indicating a potential upside of 131.14%. Pacira BioSciences has a consensus price target of $47.40, indicating a potential upside of 56.28%. Given OPKO Health's higher probable upside, analysts plainly believe OPKO Health is more favorable than Pacira BioSciences.
Pacira BioSciences has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
64.6% of OPKO Health shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 47.3% of OPKO Health shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Pacira BioSciences received 312 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 71.81% of users gave Pacira BioSciences an outperform vote while only 65.70% of users gave OPKO Health an outperform vote.
Pacira BioSciences has a net margin of 10.34% compared to OPKO Health's net margin of -31.44%. Pacira BioSciences' return on equity of 12.98% beat OPKO Health's return on equity.
In the previous week, OPKO Health had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 8 mentions for OPKO Health and 7 mentions for Pacira BioSciences. OPKO Health's average media sentiment score of 0.30 beat Pacira BioSciences' score of 0.03 indicating that OPKO Health is being referred to more favorably in the media.
Summary
Pacira BioSciences beats OPKO Health on 11 of the 17 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
